mohammadsadegh parsaee

The drug-eluting stent (DES) decreases the rate of coronary restenosis and re-obstruction. The aim of this study was to assess prospectively the effectiveness of the new generation DES on the left ventricular (LV) systolic and diastolic functions in patients with isolated severe proximal left anterior descending (LAD) coronary artery stenosis. A prospective study was conducted on 50 patients with isolated severe proximal LAD stenosis. Successful percutaneous coronary intervention (PCI) with Everolimus-eluting stents was performed for the whole study population. All the patients underwent transthoracic echocardiography within 24 hours before and one month after PCI, and LV systolic and diastolic parameters were compared before and after PCI using the paired samples t-test. The mean age of the study population was 57.68 ± 8.82 years. Within the study population, 26 (52%) patients were male and 24 (48%) were female. There was a significant 10.6% and 5.2% increase in the early diastolic mitral annular motion (e'') and the LV ejection fraction following PCI, respectively (p value = 0.005 and p value = 0.044, respectively). Before PCI, wall motion abnormality was seen in 2.21 ± 2.91 segments, which significantly decreased to 1.49 ± 2.58 segments (p value = 0.04) after the procedure. Also, the wall motion score index was 1.18 ± 0.26 before PCI, which significantly decreased to 1.13 ± 0.23 after PCI (p value < 0.001). Also, there was a trend toward a higher ratio of transmitral peak early diastolic velocity to peak late diastolic velocity after PCI (p value = 0.068). Our study showed that the use of the Everolimus-eluting stents improved the LV systolic and diastolic functions in patients with isolated severe LAD stenosis.

Background and Coronary artery disease (CAD) is the first cause of death in modern societies. It is also the first cause for individual health care cost. Multiple risk factors are mentioned for its development among which elevated uric acid is recently introduced as an inflammatory factor. This study was performed for evaluating the serum uric acid level and severity of CAD determined by coronary angiography in patients with chronic stable angina after considering and adjusting other risk factors such as age, smoking (C.S), hypertension (HTN), hyperlipidemia (HLP) and diabetes mellitus (DM). This cross-sectional analytic study was performed in 200 patients with chronic stable angina to determine the relationship between the level of serum uric acid and severity of coronary atherosclerosis in angiography. Other common cardiovascular risk factors including age, DM, HTN, HLP and C.S were also considered. A total of 78 women (39%) and 123 men (61%) were included in the study. There were no significant differences between sex and risk factors including DM, HTN, HLP, C.S, age and serum uric acid level. In the studied population, the mean severity of coronary atherosclerosis score measured by Gensini score was 15.8± 10.7 and the mean level of uric acid was 10.5±6mg/dl. Significant correlation was seen in severity of coronary atherosclerosis and level of serum uric acid in the study population (r=0.51, 0.537, respectively P<0.0001). Also, there was significant correlation between coronary atherosclerosis severity and HTN, age, DM and HLP. Multivariate analysis showed 15% contribution of serum uric acid level in developing coronary atherosclerosis. This study showed an independent relationship between serum uric acid level and severity of coronary atherosclerosis.